학술논문
Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD plus C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15280020